We report herein the design and synthesis via click chemistry of twelve novel triazole retinoid analogues of tamibarotene (AM80) and the evaluation of their anticancer activities against six cancer cell lines: HL60, K562, 786, HT29, MCF7 and PC3. Among the synthesized compounds, two were more potent than tamibarotene against solid tumor cells, and one of them had similar potency to tamibarotene against HL60 cells. The bioisosteric exchange between the amide group and the 1,2,3-triazole core in the retinoid agent tamibarotene (AM80) reported in this work is a valid strategy for the generation of useful compounds against cancer.
Introduction
In recent years, cancers have been responsible for 8.2 million human deaths worldwide. 1, 2 The rising demand for effective and safer anticancer drugs has led several research groups to develop new strategies to synthesize a wide range of anticancer molecules and to evaluate their biological anticancer activities. 2 Retinoids are class of chemical compounds that are derivatives of vitamin A with a large number of biological processes. 3 Retinoids were originally developed to treat skin disorders, but these compounds have other potential therapeutic uses, such as in type II diabetes, viral infection, metabolic diseases, Alzheimer's disease, and, primarily, cancer, due to their effects on growth differentiation and apoptosis. [3] [4] [5] The biological effects of retinoids result from their modulation of retinoic acid receptors (RARs) and retinoic X receptors (RXRs), each having three target subtypes: α, β and γ. [3] [4] [5] RARα receptor have important role in hematopoiesis. Agonists of RARα receptor are used against acute promyelocytic leukemia (APL), and in the chemoprevention of estrogen receptor-positive (ER-positive) breast cancer cell line. Studies have showed that normal RARβ signaling is important factor in the control of certain types of cancers. RARγ receptor, for instance, is important for the skin functioning and their agonists have been used in dermatology for the treatment of acne, pysoriasis and photodamaged skin. 6 RXR receptors have important role in metabolic diseases, as type II diabetes. Their agonists have also been used in the chemoprevention of breast cancer. 6 Among several retinoid anticancer compounds, here we consider the pan-RAR agonists ATRA 1 (natural ligand) [3] [4] [5] and TTNPB 2 (synthetic ligand), [3] [4] [5] the pan-RXR agonist bexarotene 3, [3] [4] [5] [6] [7] [8] [9] the selective RARα receptor synthetic agonists AM80 4 [3] [4] [5] [6] [7] [8] [9] and AM580 5, [3] [4] [5] [6] [7] [8] [9] and UVI2007 6, an RARβ agonist 10 ( Figure 1 ). The molecular structures of retinoids can be divided into three parts: a hydrophobic region, a linker unit, and a polar terminus ( Figure 2 ). Molecular modifications [3] [4] [5] [6] [7] [8] [9] [10] can provide information about the structure-activity relationships (SARs) of these compounds.
The introduction of an amide group in the linker unit during the synthesis of tamibarotene (AM80) 4 and AM580 5 has yielded compounds with increased selectivity for the RARα receptor, because the amide group does hydrogen bond interactions with the Ser232 residue. 3, 7 In comparison, ATRA 1 and TTNPB 2 (Figure 1 ), which contains a nonpolar vinyl linker, do not interact with Ser 232; therefore, these compounds can be considered pan-RAR agonists. 3, 7 Compounds 1 and 4 were identified as effective anticancer agents for the treatment of acute promyelocytic leukemia (APL) by inducing the differentiation or inhibition of cell proliferation. As a consequence of these powerful biological effects, all-trans retinoic acid (ATRA) and tamibarotene 4 have been used clinically to treat APL. [11] [12] [13] [14] However, tamibarotene (AM80) 4 is ten times more potent than ATRA in inducing differentiation of HL60 and NB-4 cells, and it has lower drug resistance against APL cancer.
13,14 Tamibarotene 4 has fewer side effects on the dermal epithelium than ATRA because it does not bind to the RARγ receptor. Although tamibarotene 4 being less toxic than ATRA, side effects still have limited its use in the long-term treatment against APL cancer.
13,14
Considering our research group's interest in synthesizing novel anti-cancer agents, we focused our studies on the development of novel retinoid molecules based on the tamibarotene structure.
The compounds were designed using classical modification strategies, such as the use of bioisosterism ( Figure 2 ). The 1,2,3-triazole rings are effective amide surrogates due to their strong dipole moments, their similarities in terms of distance and planarity, and also, as the amides, 1,2,3-triazole core can make hydrogen bonds. 15 We chose 1,2,3-triazole moiety because it have also been found in anticancer substances, 16 and it is more metabolic stable than amines. 15 Thus, we believe that novel 1,2,3-triazole retinoids designed herein, also may be a selective RARα agonist as tamibarotene 4, and this approach may contribute to obtain new derivatives with improved anticancer activities.
The carboxylic acid unit was also modified to obtain SAR information for 7-17 ( Figure 2 ). 17 The unknown 1,5-diaryl-1,2,3-triazolic retinoid derivative 18 was designed with the goal of comparing its anticancer activities with those of compound 7. 
Results and Discussion
To synthesize the 1,2,3-triazole core, it was used a click chemistry approach. 18 Some important characteristics of click reactions in organic synthesis are their modular nature, high yields of products, broad scope, ability to isolate products without chromatographic methods, use of solvents with low toxicity, and stereospecificity, which makes these methods very useful in organic synthesis. 18 Another important characteristic of the click chemistry approach in medicinal chemistry is the possibility to rapidly synthesize a library of compounds with broad structural diversification in order to obtain new molecules with improved biological activity. 19 The synthetic procedures for obtaining compounds 7-9 are shown in Scheme 1. The construction of 1,2,3-triazole cores in click reactions depends on the reaction between two building blocks, terminal acetylenes and azides. 18, 19 The synthesis was initiated by the reaction of 2,5-dimethyl-2,5-hexanediol 19 with 37% hydrochloric acid for 64 h at room temperature, generating 2,5-dichloro-2,5-dimethyl hexane 20 in 85% yield (Scheme 1). 6 Then, Friedel-Crafts alkylation of 20 with an excess of benzene 21 using AlCl 3 as a catalyst provided 1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene 22 in 82% yield, 6, 20 which was then reacted with an NBS/TsOH/CH 3 OH system for 48 h under reflux to produce bromotetrahydronaphthalene 23 (Scheme 1). 21 Subsequently, a Sonogashira cross-coupling reaction between bromide 23 and 2-methyl-3-butyn-2-ol 24 using PdCl 2 (PPh 3 ) 2 and CuI as cocatalysts and Et 3 N as a base produced the acetylenic alcohol 25 in 81% yield. 20, 22 The retro-Favorskii reaction of 25 with KOH under reflux in toluene generated the terminal acetylene 26 with 70% yield. 20, 22 Next, the aromatic azides 28a-c were prepared by the reaction of aromatic amines 27a-c with t-BuONO/TMSN 3 using the protocol reported by Moses and co-workers. 23 1,3-Dipolar cycloaddition occurred when terminal acetylene 26 reacted with aryl azides 28a-c using CuSO 4 . H 2 O, sodium ascorbate and CH 2 Cl 2 /H 2 O 1:1 as the solvent, yielding the ester-triazole compounds 29a-c in 80 to 89% yield. 24 Subsequent hydrolysis of 29a-c with NaOH in EtOH/THF produced triazole-carboxylic acid retinoids 7-9 with 78 to 95% yield (Scheme 1). molecular modification in the aryl carboxylic unit were synthesized by reaction of the terminal acetylene 26 and aryl azides 28d-i with different aromatic substitution patterns (Scheme 2).
The positional isomer 17 was also synthesized to compare its biological activity with that of 7 (Scheme 3). The synthesis of triazole 17 was initiated by nitration 21 of 1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene 22, generating nitro tetrahydronaphthalene 30, 26 which was reduced to the corresponding amine 31 using the Fe 0 /CaCl 2 /EtOH system. 27 Compound 31 was subsequently transformed into the corresponding tetrahydronaphthalene azide 32 in 78% yield using t-BuONO/TMSN 3 (Scheme 3). 23 Next, the acetylene alcohol 34 was obtained in 90% yield from the Sonogashira cross-coupling-type reaction between the ethyl 4-bromobenzoate 33 and 2-methyl-3-butyn-2-ol 24 using a PdCl 2 (PPh 3 ) 2 /CuI system and Et 3 N as base. 20, 22 The terminal acetylene 35 was obtained in 65% yield via retro-Favorski reaction of acetylene alcohol 34 with excess NaH in hexane under reflux for 48 h (Scheme 4). 28 T h e 1 , 3 -d i p o l a r c y c l o a d d i t i o n o f a r y l tetrahydronaphthalene azide 32 and terminal acetylene 35 afforded the ester triazole compound 36 in 85% yield. 24 Hydrolysis reaction of 36 with NaOH generated the positional isomer 17 in 93% yield (Scheme 5). 25 Finally, compound 18 was synthesized using Fokin's methodology 29 by reaction between terminal acetylene 27 and azide ester 29a with 3 equiv. of potassium tert-butoxide in dimethyl sulfoxide (DMSO) in order to compare the anticancer activity of compound 18 with those of 7 and 17.
Unlike Fokin and co-workers, 29 an excess of t-BuOK was used, allowing one-pot preparation of compound 18 without requiring a deprotection step.
Biological activity
All triazole retinoid analogues synthesized were evaluated for antiproliferative activity ( 10 The chloro introduction in 7 selectively increased its anticancer activity for the 786 and HT-29 cells.
Compound 10, containing an SO 2 NH 2 group at the para position, which can be considered a bioisosteric substitute for carboxylic acid, 32 had poor activity against all cancer cell lines tested ( 
Conclusions
In summary, 12 novel 1,2,3-triazole retinoid 7-18 derivatives of tamibarotene (AM80) 4 were synthesized and evaluated for in vitro anti-cancer activity.
Among the compounds synthesized, triazole 7 stands out, because it is equipotent to tamibarotene 4 in relation to the anticancer activity against HL60 cells (Table 1 , entries 1-2). With respect to solid tumor cells, triazole 7 is more active for all cancer cells tested when compared to tamibarotene 4, with prominent anticancer activity for the HT-29 colorectal adenocarcinoma cell line (6.7 μM) and with good selectivity index (SI = 3.6). Compound 9 showed the lowest cytotoxicity among compounds synthesized.
Compound 16, an aminoretinoid triazole containing an NH 2 group at the para position, had good anticancer activity against all solid tumor cells tested. 16 is the most potent anti-cancer compound for breast cancer (MCF-7 cells) of this work, and new studies are being conducted to obtain new analogues of 16 aiming to obtain more potent compounds and with less cytotoxicity.
Positional isomer 17 had lower potency than triazole 7, indicating that obtaining a positional isomer of 1,4-diaryl-1,2,3-triazole compounds is a critical factor in studies about biological anti-cancer activities.
Experimental

General remarks
All solvents were distilled before use according to the standard procedure. All reactions were performed under an atmosphere of dry nitrogen and monitored by thin layer chromatography (TLC) using prepared plates (silica gel 60 F254 on aluminum). The chromatograms were examined under both 254 and 360 nm UV light or with the developing agent ethanolic vanillin and heat. Flash column chromatography was performed on silica gel 60 (particle size 200-400 mesh ASTM, purchased from Aldrich, USA) and eluted with hexane or hexane/ethyl acetate in different ratios. Melting points were determined using Fisatom 430D equipment. Infrared (IR) spectra were recorded on a Nicolet ), AlCl 3 (0.2 mmol) was added and the reaction mixture was stirred under reflux in nitrogen atmosphere for 64 h. Excess benzene 21 was distilled off and the resulting mixture was poured into distilled water. The mixture was extracted with ethyl acetate and the organic phase was dried over MgSO 4 . The solvent was removed under vacuum. The residue was purified by distillation at low pressure (0.5 mm Hg), and the product 22 was collected between 90 and 120 °C as a colorless oil in 82% yield. The product was purified by flash chromatography on silica gel using hexane as eluent, to give 34 as a yellow oil in 70% yield. 1 General procedure for the preparation of 6-ethynyl-1,1,4,4-tetra methyl-1,2,3,4-tetrahydronaphthalene 26 38, 39 To a solution of acetylene alcohol 25 (3.0 mmol) in toluene (9.0 mL mmol -1 ) under nitrogen atmosphere, KOH (9.0 mmol) was added. The reaction mixture was refluxed at 110 °C for 20 h and excess toluene was removed by distillation. The residue was extracted with ethyl acetate and the organic phase was dried over MgSO 4 . The solvent was removed under vacuum. The product was purified by flash chromatography on silica gel using hexane as eluent. The product 25 was obtained as a yellow oil in 70% yield. 1 General procedure for the preparation of the azides 28a-i and 32 23 To a solution of amine 27a-i and 31 (2.0 mmol) in acetonitrile (3.8 mL mmol -1 ), t-BuONO (4.3 mmol) and TMSN 3 (3.26 mmol) were added dropwise under a nitrogen atmosphere, at 0 °C. The reaction mixture was stirred at room temperature for 2 h. The solution was poured into water, extracted with ethyl acetate and the organic phase was dried over anhydrous MgSO 4 . The solvent was removed under vacuum.
Ethyl 4-azidobenzoate (28a) 43 The compound was used without purification and it was obtained as an orange oil in 96% yield. 44 The product was purified by flash chromatography on silica gel using a hexane/ethyl acetate (94:6) solution as the mobile phase, which furnished the product as a yellow oil in 80% yield. 
4-Azidobenzenesulfonamide (28d) 45
The product was purified by flash chromatography on silica gel using a hexane/ethyl acetate (60:40) solution as eluent, which furnished the product as white crystals in 50% yield. 1 1-Azido-4-methoxybenzene (28e) 46 The product was purified by flash chromatography on silica gel using a hexane/ethyl acetate (95:5) solution as the mobile phase, which furnished the product as yellow crystals in 73% yield. 1 4-Azido-1,2-dimethoxybenzene (28f) 46 The product was purified by flash chromatography on silica gel using a hexane/ethyl acetate (70:30) solution as the mobile phase, which furnished the product as yellow crystals in 78% yield. 1 46 The product was purified by flash chromatography on silica gel using a hexane/ethyl acetate (90:10) solution as the mobile phase, which furnished the product as yellow crystals in 87% yield. 1 46 The product was purified by flash chromatography on silica gel using hexane as the mobile phase, which furnished the product as a brown oil in 75% yield. 
1-Azido-4-nitrobenzene (28i) 47
The product was purified by flash chromatography on silica gel using hexane as the mobile phase, which furnished the product as yellow crystals in 79% yield. 1 6-Azido-1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-naphthalene (32) The product was purified by flash chromatography on silica gel using hexane as the mobile phase, which furnished the product as a brown oil in 86% yield. IR (KBr) ν / cm The product 11 was purified by flash chromatography on silica gel using a hexane/ethyl acetate (80: 20) The product 12 was purified by flash chromatography on silica gel using a hexane/ethyl acetate (85:15) solution as eluent, which furnished the product as white crystals in 62% yield. mp 126 °C; IR (KBr) ν / cm The product 13 was purified by flash chromatography on silica gel using a hexane/ethyl acetate (85:15) solution as the mobile phase, which furnished the product as white crystals in 84% yield. mp 99 °C; IR (KBr) ν / cm The product 14 was purified by crystallization in a hexane/ethyl acetate (70: 30) The product 15 was purified by flash chromatography on silica gel using a hexane/ethyl acetate (90:10) solution as the mobile phase, which furnished the product as yellow crystals in 61% yield. The product 29a was purified by flash chromatography on silica gel using a hexane/ethyl acetate (98:2) solution as the mobile phase, which furnished the product as yellow crystals in 82% yield. mp 155 °C; IR (KBr) ν / cm The product 29c was purified by crystallization from hexane and was obtained as white crystals in 80% yield. mp 121 °C; IR (KBr) ν / cm To a solution of 29a-c or 36 (1 mmol) in ethanol 96% (7 mL mmol -1 ), NaOH (18.75 mmol) was added. The mixture was stirred at room temperature for 24 h. To the final solution, 37% HCl was added until pH = 2. Then the solution was extracted with ethyl acetate. The organic phase was dried over anhydrous MgSO 4 , and the solvent was then removed under vacuum. The products were purified by crystallization from hexane/ethyl acetate (70:30). To a solution of terminal acetylene 27 (1 mmol) and aryl azide 29a (1 mmol) in DMSO (3 mL), potassium t-butoxide (3 mmol) was added under nitrogen atmosphere. The mixture was stirred for 96 h at 40 °C. Then, a 37% HCl solution was added until pH = 3. The reaction mixture was extracted with ethyl acetate and the organic phase was dried over anhydrous MgSO 4 . The solvent was removed under reduced pressure. The product 18 was obtained as yellow crystals in 75% Cytotoxicity assay 30, 48, 49 Cell lines
Six strains of human tumor cells were used: 786-0 (ATCC-CRL-1932, kidney carcinoma), HT-29 (ATCC-HTB-38, colon carcinoma), MCF-7 (ATCC-HTB-22, breast adenocarcinoma), PC-3 (PC-3 ATCC-CRL-1435, prostatic adenocarcinoma), HL-60 (ATCC-CCL-240, promyelocytic leukemia) and K-562 (ATCC-CCL-243, chronic myelogenous leukemia). The strains were donated by Professor Dr João Ernesto de Carvalho (CPQBA-UNICAMP) and stored under liquid nitrogen. For cytotoxicity assays, the cells were thawed in RPMI-1640 medium supplemented with 10% fetal calf serum and 1% streptomycin-penicillin, then maintained in an incubator with 5% CO 2 at 37 °C in a humid environment for growth.
Sample preparation for analysis
The samples were prepared by adding DMSO (0.1 g mL -1 ) and then diluted in complete medium to achieve a maximum DMSO concentration of 0.25%.
Cell preparation
For cell counting, the complete medium was aspirated then 0.5 mL of EDTA-trypsin (1 mM EDTA, 0.25% trypsin) in PBS, pH 7.4, was added. The cells were kept in an incubator for 3-5 min. After centrifugation for 4 min at 1000 rpm, trypsin and the medium were discarded and fresh medium was added to obtain a cell suspension. For non-adherent cells the suspension was obtained by centrifugation.
Cytotoxicity activity evaluation
Cells were placed in 96-well plates (test-plate and T0-plate) (1 × 10 4 cells plate -1 for adherent cells, and 2.5 × 10 4 cells plate -1 for non-adherent cells). After 24 h at 37 °C in an atmosphere of 5% CO 2 and 100% relative humidity, the cells were exposed to 4 different concentrations of each compound: 0.25, 2.5, 25 and 250 μg mL -1 for 48 h. The adherent cells were then fixed with 100 μL of 40% trichloroacetic acid (TCA), incubated for 30 min at 4 °C and colored using sulforhodamine B (SRB) according to the methodology described by Skehan and co-workers. 30 For non-adherent cells, at the end of the exposure time to the substances, the medium was removed and replaced with 0.2 mL of fresh MTT solution (final concentration 0.5 mg mL -1 ). The plates were incubated at 37 °C for 4 h. After the incubation, the medium was removed and insoluble MTT crystals and formazan were dissolved by adding 0.2 mL of DMSO and the optical densities were read in a spectrophotometric plate reader at 540 nm.
The concentrations of tamibarotene (Sigma-Aldrich 
Supplementary Information
Supplementary data are available free of charge at http://jbcs.sbq.org.br as PDF file.
